Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press69410.36691/RJA694ArticlesСтатьиResearch ArticleBIOMARKERS ALLERGIC INFLAMATION AND SEVERITY OF ATOPIC DERMATITIS AT CHILDRENБИОМАРКЕРЫ АЛЛЕРГИЧЕСКОГО ВОСПАЛЕНИЯ И ТЯЖЕСТЬ АТОПИЧЕСКОГО ДЕРМАТИТА У ДЕТЕЙVarlamovE EБарламовЕ ЕVinogradovaT VБиноградоваТ БChuslyaevaA AЧусляеваА АOkunevaT SОкуневаТ СPampuraA NПампураА Нapampura@pedklin.ruMoscow Research Institute of Pediatrics and Child SurgeryФГБУ «Московский научно-исследовательский институт педиатрии и детской хирургии» Минздравсоцразвития России1510201295NO5 (2012)№5 (2012)313510032020Copyright ©; 2012, Pharmarus Print MediaCopyright ©; 2012, Фармарус Принт Медиа2012Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/694

Background.To establish the relationship between the serum concentrations of IL4, IL5, eotaxin, eotaxin2, ECP and the severity of atopic dermatitis in children. Methods. The study included 40 children with atopic dermatitis, patients were divided into two clusters with KMeans method, index SCORAD was taken as a criterion of clustering. All patients were conducted to determine the concentration of IL4, IL5, eotaxin, eotaxin2, ECP. Results. The SCORAD index was significantly higher in the second cluster in comparison to the first one. In second cluster the level of eotaxin2 was significantly higher, in terms of the ECP, IL4, IL5,eotaxin patient groups did not differ. The second cluster was characterized by patients with a concentration of IL5 of 1,5 p/ml. Conclusion. In assessing the severity of allergic inflammation in atopic dermatitis concentration of eotaxin2 was most informative.

Цель. Установить взаимосвязь концентрации интерлейкина (ИЛ)-4, ИЛ-5, эотаксина, эотаксина-2, эозинофильного катионного протеина (ЭКП) в сыворотке крови с тяжестью атопического дерматита (АтД) у детей. Материалы и методы. Б исследование включены 40 детей с АтД, методом к-средних пациенты были распределены на два кластера. Б качестве критерия кластеризации было принято значение индекса SCORAD. Всем пациентам методом иммуноферментного анализа проводилось определение концентрации ИЛ-4, ИЛ-5, эотаксина, эотаксина-2, ЭКП. Результаты. Значение индекса SCORAD было достоверно выше во втором кластере в сравнении с первым. У детей второго кластера уровень эотаксина-2 достоверно выше, по уровню ЭКП, ИЛ-4, ИЛ-5, эотаксина группы пациентов не различались. Для второго кластера были характерны пациенты с концентрацией ИЛ-5 ниже 1,5 пг/мл. Заключение. При оценке степени выраженности аллергического воспаления при АтД наибольшей информативностью обладает концентрация эотаксина-2.

atopic dermatitiscytokinesIL-4IL-5eotaxineotaxin-2ECPатопический дерматитцитокиныэотаксинэотаксин-2Williams H., Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J. Allergy Clin. Immunol. 2006, v. 118, p. 209-213.Novak N., Leung D.Y. Advances in atopic dermatitis. Curr. Opin. Immunol. 2011, v. 23 (6), p. 778-783.Bieber T, Cork M., Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy. 2012, v. 67, p. 969-975.Damps-Konstanska I., Gruchata-Niedoszytko M., Wilkowska A. et al. Serum eosinophil cationic protein in patient with perennial rhinitis and atopic dermatitis, allergic to house dust mites. Pol. Merkur. Lekarski. 2005, v. 19, p. 765-768.Pucci N., Novembre E., Cammarata M. et al. Scoring atopic dermatitis in infants and young children: distinctive features of SCORAD index. Allergy. 2005, v. 60, p. 113-116.Murat-Susic S., Lipozencic V., Hrusa K. et al. Serum eosinophil cationic protein in children with atopic dermatitis. J. Dermatol. 2006, v. 45, p. 1156-1160.Foster E., Simpson E., Fredrikson L. Eosinophils Increase Neuron Branching in Human and Murine Skin and In Vitro. PLoS ONE. 2011, v. 6, p. 22029.Mosmann TR., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 1989, v. 7, p. 145-173.Murphy K.M., Reiner S.L. The lineage decisions of helper T-cells. Nature Rev. Immunol. 2002, v. 2, p. 933-944.Clinical Immunology. Principles and Practice. Robert R. Rich, Thomas A. Fleisher, William T Shearer, Harry W Schroeder Jr., Anthony J. Frew, and Cornelia M. Weyand. Elsevier Limited. 2008, p. 1558.Matsuura H., Ishigura A., Hiroyuki A. et al. Elevation of plasma eotaxin levels in children with food allergy. Jpn. J. Clin. Immunol. 2009, v. 32 (3), p. 180-185.Смирнова М.О., Окунева ТС., Ружиская Е.А. и соавт. Клиническая значимость определения уровня эозинофильного катионного протеина у детей с атопическим дерматитом. Рос. вест. перинатал. и педиат. 2010, № 4, с. 94-97.Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm. Venerol. (Stock.). 1980, v. 92, p. 44-47.Eichenfield L.F., Hanifin C.J., Luger TA. et al. Consensus Conference on Pediatric Atopic Dermatitis. J. Am. Acad. Dermatol. 2003, v. 49, p. 1088-1095.Lamkhioued B. et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J. Immunol. 1997, v. 159, p. 4593-4601.Yamada H. et al. Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. Allergy. 2000, v. 55, p. 392-397.Taha R. et al. Increased expression of the chemoattractant cytokines eotaxin, monocyte chemotactic protein-4, and interleukin-16 in induced sputum in asthmatic patients. Chest. 2001, v. 120, p. 595-601.Taha R. et al. Evidence increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J. Allegy Clin. Immunol. 2000, v. 105, p. 1002-1007.Kagami S., Kakinuma T., Saeki H. et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/ CCL24, in patients with atopic dermatitis: serum eotaxin-3/ CCL26 levels reflect the disease activity of atopic dermatitis. Clin. Exp. Immunol. 2003, v. 134, p. 309-313.Owczarec W., Palpinska M., Targowski T. et al. Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis. Cytocine. 2010, v. 50, p. 181-185.Leung D. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin. Exp. Immunol. 1997, v. 107, p. 25-30.Kaburagi Y., Shimada Y., Nagaoka T. et al. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol. Res. 2001, v. 293, p. 350-355.Schmitt J., Schäkel K., Schmitt N., Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm. Venereol. 2007, v. 87 (2), p. 100-111.Walling H.W., Swick B.L. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investing Dermatol. 2010, v. 28(3), p. 99-117.